Sorafenib efficacy for treatment of HCC recurrence after liver transplantation is an open issue

Journal of Hepatology

Volumn 60, Issue 3, 2014, Pages 681-

  Mancuso, Andrea ^a   Mazzarelli, Chiara ^a   Perricone, Giovanni ^a   Zavaglia, Claudio ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMAN; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; NEOPLASM RECURRENCE, LOCAL;

CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; NEOPLASM RECURRENCE, LOCAL; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 84894061035     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.10.030     Document Type: Letter

References (10)

1. C. Sposito, L. Mariani, A. Germini, M.F. Reyes, M. Bongini, and G. Grossi et al. Comparative efficacy of sorafenib vs. best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study J Hepatol 59 2013 59 66
2. C. Toso, G. Mentha, and P. Majno Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence J Hepatol 59 2013 3 5
3. S. Bhoori, S. Toffanin, C. Sposito, A. Germini, A. Pellegrinelli, and A. Lampis et al. Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle J Hepatol 52 2010 771 775
4. P. Newell, S. Toffanin, A. Villanueva, D.Y. Chiang, B. Minguez, and L. Cabellos et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo J Hepatol 51 2009 725 733
5. T.C. Gangadhar, E.E. Cohen, K. Wu, L. Janisch, D. Geary, and M. Kocherginsky et al. Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies Clin Cancer Res 17 2011 1956 1963
6. C. Zavaglia, A. Airoldi, A. Mancuso, M. Vangeli, R. Vigano, and G. Cordone et al. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature Eur J Gastroenterol Hepatol 25 2013 180 186
7. K. Staufer, L. Fischer, B. Seegers, E. Vettorazzi, B. Nashan, and M. Sterneck High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation Transpl Int 25 2012 1158 1164
8. A. Weinmann, I.M. Niederle, S. Koch, M. Hoppe-Lotichius, M. Heise, and C. Duber et al. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation Dig Liver Dis 44 2012 432 437
9. A.C. Piguet, B. Saar, R. Hlushchuk, M.V. St-Pierre, P.M. McSheehy, and V. Radojevic et al. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma Mol Cancer Ther 10 2011 1007 1017
10. A. Mancuso, A. Airoldi, R. Vigano, and G. Pinzello Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation Dig Liver Dis 43 2011 754